Table 1.

Summary of major findings on GR expression regulation in HUVECs

Figure 1: GR mRNA isoform levels	Resistant cells have higher expression of GR isoforms 1C and 1D, and lower expression of isoform 1F than sensitive cells in basal conditions.
	Dexamethasone-treatment downregulated 5′UTR mRNA isoform 1C and 3′UTR mRNA isoform α in resistant cells only.
Figure 2: Effect of GR-1Cα Overexpression	GR-1Cα overexpression in resistant cells did not improve in vitro response to dexamethasone as determined by NOS3 downregulation, SERPINE1 upregulation, and decreases in aPTT.
	GR-1Cα overexpression further downregulated the expression of 5′UTR mRNA isoforms 1B (in resistant cells only) and 1H in both sensitivity groups.
Figure 3: GR promoter activity	There were no significant differences in basal GR promoter (unmethylated) activity between sensitive and resistant cells.
	Dexamethasone treatment decreased promoter 1F activity in both sensitivity groups, decreased promoter 1B activity in resistant cells only and increased promoter 1D activity in sensitive cells only.
	Promoter activity differences between sensitive and resistant cells did not correlate with differences in GR 5′UTR mRNA levels.
Figure 4: GR promoter methylation and AZA treatment	Sensitive cells have higher promoter 1D methylation levels and lower promoter 1F and 1H methylation levels compared to resistant cells.
	Promoter methylation levels correlated with GR 5′UTR mRNA levels.
	AZA treatment upregulated the expression of all GR mRNA isoforms except isoform 1D in resistant cells.
	AZA treatment improved in vitro dexamethasone response in resistant cells as determined by NOS3 downregulation and SERPINE1 upregulation.